A new and highly capitalized market player has boldly declared its debut as a developer of allogeneic, off-the-shelf iPCS-derived cell therapeutics. GC Therapeutics (GCTx) has officially launched, bringing with it a revolutionary approach to cell therapy that aims to overcome current challenges in scalability, efficiency, and cost-effectiveness that have traditionally hindered the development of iPSC-derived therapies. With the debut of its innovative TFome™ platform, GCTx is positioned to scale the full potential of induced pluripotent stem cell (iPSC)-based therapies. [Read more…]
Immunofluorescent Staining Within Hours, Not Days
AMSBIO has launched CellO-IF – an all-in-one immunofluorescent staining reagent kit designed to accelerate the labelling organoids and spheroids directly in hydrogels or extracellular matrices, while preserving delicate structures and cellular integrity.
Immunofluorescence (IF) allows detection and localization of antigens in diverse types of tissues in various cell preparations. The technique provides excellent sensitivity and amplification of signal by comparison to immunohistochemistry. However, traditional IF staining is a labor intensive, multi-step process. CellO-IF revolutionizes this by streamlining the procedure. [Read more…]
StemCyte’s HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment
BALDWIN PARK, Calif., Oct. 3, 2024 — StemCyte announced today that its Hematopoietic Progenitor Cell Cord Blood therapy (HPC Cord Blood) has officially obtained the Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the treatment of Long COVID-19 syndrome. StemCyte is one of the few cell therapy companies in the United States to receive the FDA-granted RMAT designation. [Read more…]
South Korea’s SK bioscience Completes Acquisition of Germany’s CDMO IDT Biologika
SK bioscience completed the acquisition of German CDMO company IDT Biologika with over a century of history that enables immediate expansion in revenue and infrastructure.
The company aims to double sales of IDT Biologika by 2028 through new business projects and operational efficiency.
The company will invest in high-growth businesses such as stage cell and gene therapy (CGT) and recombinant vaccine.
SK bioscience will accelerate its global push based on the complementary capabilities of both companies.
Cell Therapy in Asia Erupts with Partnerships and Joint Ventures
Cell therapy in Asia has been gathering momentum over the past several years. Japan accelerated its position as a hub for regenerative medicine research, largely driven by support from Prime Minister Shinzo Abe, who identified regenerative medicine and cellular therapy as key to the Japan’s strategy to drive economic growth.
China, South Korea, and other Asian nations have also taken measures to support cell therapy development within their borders. [Read more…]
- « Previous Page
- 1
- …
- 89
- 90
- 91
- 92
- 93
- …
- 338
- Next Page »